Clinical and genetic risk factors for cystic fibrosis-related liver disease

Pediatrics

Volumn 103, Issue 1, 1999, Pages 52-57

  Wilschanski, Michael ^a   Rivlin, Joseph ^b   Cohen, Solomon ^a   Augarten, Arieh ^c   Blau, Hannah ^d   Aviram, Micha ^e   Bentur, Lea ^f   Springer, Chaim ^g   Vila, Yael ^h   Branski, David ^a   Kerem, Batsheva ^a   Kerem, Eitan ^a,i  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b CARMEL MEDICAL CENTER   (Israel)

^c SHEBA MEDICAL CENTER   (Israel)

^d SCHNEIDER CHILDREN S MEDICAL CENTER OF ISRAEL   (Israel)

^e BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^f RAMBAM MEDICAL CENTER   (Israel)

^g HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^h Ichilov Medical Center   (Israel)

ⁱ SHAARE ZEDEK MEDICAL CENTER   (Israel)

Author keywords

Cystic fibrosis; Genotype; Liver disease; Phenotype; Risk factors

Indexed keywords

BILIRUBIN; LIVER ENZYME;

ADOLESCENT; ADULT; ARTICLE; CHILD; CHRONIC LIVER DISEASE; CONTROLLED STUDY; CYSTIC FIBROSIS; FEMALE; GENETICS; GENOTYPE; HUMAN; INTESTINE OBSTRUCTION; ISRAEL; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MECONIUM ILEUS; MUTATION; NUTRITIONAL STATUS; PANCREAS INSUFFICIENCY; PHENOTYPE; PRIORITY JOURNAL; RISK FACTOR;

ADOLESCENT; ADULT; ARABS; CHILD; CHILD, PRESCHOOL; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; EXOCRINE PANCREATIC INSUFFICIENCY; FEMALE; GENOTYPE; HUMANS; INFANT; ISRAEL; JEWS; LIVER DISEASES; LOGISTIC MODELS; MALE; MIDDLE AGED; MUTATION; PHENOTYPE; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 0032975778     PISSN: 00314005     EISSN: None     Source Type: Journal    
DOI: 10.1542/peds.103.1.52     Document Type: Article

References (34)

1. Welsh MJ, Tsui L-C, Boat TF, Beaudet AL. Cystic fibrosis. In: Scriver CL, Beaudet AL, Sly WS, Valle D, eds. The Metabolic Basis of Inherited Disease. 7th ed. New York, NY: McGraw-Hill; 1995:3799-3876
2. Kerem B, Rommens JM, Buchanan JA, et al. Identification of the cystic fibrosis gene: genetic analysis. Science. 1989;245:1073-1080
3. Kerem E, Corey M, Kerem B, et al. The relationship between genotype and phenotype in cystic fibrosis: analysis of the most common mutation ΔF508). N Engl J Med. 1990;323:1517-1522
4. Cystic Fibrosis Genetic Analysis Consortium. Population variations of common cystic fibrosis mutations. Hum Mutat. 1994;4:167-177
5. Cystic Fibrosis Genotype-Phenotype Consortium. Correlation between genotype and phenotype in patients with cystic fibrosis. N Engl J Med. 1993;329:1308-1313
6. Kerem E, Rave-Harel N, Augarten, et al. A CFTR splice variant with partial penetrance associated with variable cystic fibrosis presentation. Am J Respir Crit Care Med. 1997;155:1914-1920
7. Kerem E, Nissim-Rafinia M, Argaman Z, et al. A missense cystic fibrosis transmembrane conductance regulator mutation with variable phenotype. Pediatrics. 1997;100:1-6
8. Colombo C, Apostolo MG, Ferrari M, et al. Analysis of risk factors for the development of liver disease in CF. J Pediatr. 1994;124:393-396
9. Roy CC, Weber AM, Morin CL, et al. Hepatobiliary disease in cystic fibrosis: survey of current issues and concepts. J Pediatr Gastoenterol Nutr. 1982;1:469-478
10. Scott-Jupp R, Lama M, Tanner MS. Prevalence of liver disease in cystic fibrosis. Arch Dis Child. 1991;66:698-701
11. Cystic Fibrosis Foundation. Patient Registry 1996 Annual Data Report. Bethesda, MD: Cystic Fibrosis Foundation; August 1997
12. Colombo C, Battezzati PM, Podda M. Hepatobiliary disease in cystic fibrosis. Semin Liver Dis. 1994;14:259-269
13. Di Sant' Agnese PA, Blanc WA. A distinctive type of biliary cirrhosis of the liver associated with cystic fibrosis of the pancreas. Pediatrics. 1956; 188:387-409
14. Duthie A, Doherty DG, Williams C, et al. Genotype analysis of DF508, G551D, R553X mutations in children and adults with cystic fibrosis with and without liver disease. Hepatology. 1992;15:660-664
15. Kerem B, Chiba-Falik O, Kerem E. Cystic fibrosis in Jews: frequency and mutation distribution. Genet Testing. 1997;1:35-39
16. Kerem E, Kalman YM, Yahav Y, et al. Highly variable incidence of cystic fibrosis and different mutation distribution among different Jewish ethnic groups in Israel. Hum Genet. 1995;96:193-197
17. Polgar G, Promadhart V. Pulmonary Function Testing in Children: Techniques and Standards. Philadelphia, PA: WB Saunders; 1971
18. Tanner JM, Whitehouse RH, Takaishi M. Standards from birth to maturity for height, weight, height velocity and weight velocity: British children, 1965. Arch Dis Child. 1966;41:454-471
19. Highsmith WE, Lauraneli H, Burch MS, et al. A novel mutation in the cystic fibrosis gene in patients with pulmonary disease but normal sweat chloride concentrations. N Engl J Med. 1994;331:974-980
20. Augarten A, Kerem B, Yahav Y, et al. Mild cystic fibrosis and normal or borderline sweat test in patients with the 3849 + 10kb C->T mutation. Lancet. 1993;342:25-26
21. FitzSimmons SC. The changing epidemiology of cystic fibrosis. J Pediatr. 1993;122:1-9
22. O'Connor PJ, Southern KW, Bowler IM, Irving HC, Robinson PJ, Littlewood JM. The role of hepatic scintigraphy in cystic fibrosis. Hepatology. 1996;23:281-287
23. Colombo C, Castellani MR, Balistreri WF, Seregni E, Assaisso ML, Guinta A. Scintigraphic documentation of an improvement in hepatobiliary excretory function after treatment with ursodeoxycholic acid in patients with cystic fibrosis and associated liver disease. Hepatology. 1992;15:677-684
24. Gerling B, Becker M, Staab D, Schuppan D. Prediction of liver fibrosis according to serum collagen VI level in children with cystic fibrosis. N Engl J Med. 1997;36:1611-1612
25. Maurage C, Lenaerts C, Weber AM, Brochu P, Yousef I, Roy CC. Meconium ileus and its equivalent as a risk factor for the development of cirrhosis: an autopsy study in cystic fibrosis. J Pediatr Gastroenterol Nutr. 1989;9:17-20
26. Davis PB, Drumm M, Konstan MW. Cystic fibrosis. Am J Respir Crit Care Med. 1996;154:1229-1256
27. Rozmahel R, Wilschanski M, Matin A, et al. Modulation of disease severity in cystic fibrosis transmembrane conductance regulator deficient mice by a secondary genetic factor. Nature Genet. 1996;12:280-287
28. Wilschanski M, Rozmahel R, Beharry S, et al. In vivo measurements of ion transport in long-living CF mice. Biochem Biophys Res Comm. 1996; 219:753-759
29. Rave-Harel N, Kerem E, Nissim-Rafinia M, et al. The molecular basis of partial penetrance of splicing mutations in cystic fibrosis. Am J Hum Genet. 1997;60:87-94
30. Dork T, Wulbrand U, Richter T, et al. Cystic fibrosis with three mutations in the cystic fibrosis transmembrane conductance regulator gene. Hum Genet. 1991;87:441-446
31. Kiesewetter S, Macek M Jr, Davis C, et al. A mutation in CFTR produces different phenotypes depending on chromosomal background. Nature Genet. 1993;5:274-278
32. Colombo C, Setchell KDR, Podda M, et al. Effects of ursodeoxycholic acid therapy for liver disease associated with cystic fibrosis. J Pediatr. 1990;117:482-489
33. Cutting J, Lentze MJ, Reichen J. Effects of ursodeoxycholic acid treatment on nutrition and liver function in patients with cystic fibrosis and longstanding cholestasis. Gut. 1990;31:918-921
34. Galabert C, Montet JC, Lengrand D, et al. Effects of ursodeoxycholic acid on liver function in patients with cystic fibrosis and chronic cholestasis. J Pediatr. 1992;121:138-141